Plasma Apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome
- Rachel L.M. van der Ham, MD (r.l.m.van_der_ham{at}lumc.nl)1,
- Reza Alizadeh Dehnavi, MD1,
- Jimmy F.P. Berbée, PhD2,
- Hein Putter, PhD3,
- Albert de Roos, MD, PhD4,
- Johannes A. Romijn, MD, PhD2,
- Patrick C.N. Rensen, PhD2 and
- Jouke T. Tamsma, MD, PhD1
- 1Section of Vascular Medicine, Department of Endocrinology and Internal Medicine
- 2Department of Endocrinology and Internal Medicine
- 3Department of Medical Statistics
- 4Department of Radiology, Leiden University Medical Center, The Netherlands
Abstract
Objective To determine whether, in accordance with observations in mouse models, high concentrations of the lipoprotein lipase inhibitors Apolipoprotein (Apo) CI and ApoCIII are associated with increased triglyceride concentrations and decreased fat mass in men with the metabolic syndrome (MS).
Research design and methods Plasma ApoCI, ApoCIII and triglyceride concentrations were measured in the postabsorptive state in 98 men with the MS. Subcutaneous and visceral fat areas were measured by 3T-MRI.
Results Triglyceride concentrations were 49% higher, and the average visceral fat area was 26% lower (both p<0.001), in subjects with high ApoCI and ApoCIII compared to low ApoCI and ApoCIII. Subjects with either high ApoCI or ApoCIII had 16% (p<0.05) and 18% (p<0.01) decreased visceral fat area, respectively.
Conclusions High concentrations of ApoCI and ApoCIII are associated with increased triglycerides and decreased visceral fat mass in men with the MS. These findings translate mouse studies into human pathophysiology.
Footnotes
-
- Received July 18, 2008.
- Accepted September 17, 2008.
- Copyright © American Diabetes Association
